Two situations get confused here, and separating them resolves most of the question.
If the package never crosses a border, customs is not involved at any point. There is no inspection, no import decision, and nothing to seize.
If it does cross one, the package passes through an import process with a specific legal basis and a specific sequence. That sequence is administrative, not criminal, which is the second thing people get wrong.
The trap is that a domestic order is not the same thing as a domestic shipment. A website with a US address, US pricing and US customer service may still ship from overseas, and plenty do. Very few vendors at this end of the market manufacture anything themselves, and fewer still hold stock domestically.
You usually find out from the tracking number. A first scan in Hong Kong, Shenzhen or anywhere outside your own country marks the package as an import, whatever the website looked like. If you want to know before ordering, ask where it ships from and treat a vague answer as an answer.
Will my peptides get seized?
Nobody knows, and the reason is worth understanding before you weigh anybody's claim about it.
Vendors do not publish loss rates, because a published figure would be a sales problem. FDA import refusal data is public but is not broken out in a way that isolates personal-quantity peptide shipments from everything else crossing the border. And forum reports are self-selecting in both directions, because people post when a package vanishes and rarely when one arrives.
So what can be offered is a direction rather than a number. Vendors increasingly price reshipping into their offers, which is itself evidence of a loss rate they consider material. Reported import lead times have lengthened. Both are indirect. What none of that gives you is a percentage, and anybody quoting one is estimating.
Can you get in trouble for a seized package?
The question underneath the others, and it has a short answer.
An import refusal is an administrative decision about goods. It is not an arrest, a charge or a criminal referral. Nobody comes to the door over a personal-quantity peptide shipment that was refused at the border.
What does happen is recorded. Refusals go into an FDA database, and a pattern of them against the same importer or the same foreign shipper can lead to an import alert, meaning future shipments are detained automatically without physical examination.4 That mechanism is aimed at the shipper more often than the recipient, and it is why a vendor's route degrades gradually.
What happens when customs holds a package
The authority is section 801 of the Federal Food, Drug and Cosmetic Act. It lets the FDA refuse admission to anything that appears to be an unapproved drug, misbranded or adulterated.1 Most research peptides meet at least one of those descriptions, and our guide on what research use only actually means covers why the label does not change that.
Customs and Border Protection screens incoming shipments and refers anything that looks like a regulated article to the FDA, which makes the admission decision. CBP handles the package; the FDA decides whether it comes in.2
From there the sequence runs in three stages.
Detention
The shipment is held and a Notice of FDA Action is issued. The agency is alleging an appearance of violation, not proving one.
A response window
Standard practice gives around ten working days to submit testimony, request reconditioning, or ask for a hearing. With no response, the process moves to the next stage.
Refusal
The FDA issues a Notice of Refusal of Admission, and the shipment must be exported or destroyed within 90 days.3
Everywhere describes that process, and a personal peptide order follows a different one.
Why the usual advice does not apply to you
The two frameworks diverge here.
The FDA's own procedures manual covers a specific case. Where an article is a drug, is valued at $2,500 or less, and is an unapproved new drug, misbranded or adulterated, the refused product is destroyed without giving the owner the opportunity to export it.3
Nearly every personal peptide order meets all three conditions.
So the ten days, the 90-day window and the export option are the commercial framework. A personal-value order of an unapproved drug goes down the administrative destruction route instead. You may still receive notice and an opportunity to respond, and the realistic outcome is destruction and not return.
The distinction matters because vendor pages and import consultancies describe the commercial process. A reader planning around a 90-day export window is planning around the wrong one.
Does the personal importation policy cover peptides?
A discretionary FDA policy allows personal quantities of some unapproved drugs in limited cases. Usually a serious illness. No treatment at home. A doctor involved.
Two words in that sentence carry the weight. Discretionary puts the choice with the agency. It is not something you are entitled to. And the criteria describe somebody importing a treatment unavailable in their own country under medical supervision, which is not the situation of somebody ordering research-labelled vials online.
Vendor pages cite it constantly as though it were a general exemption, which it has never been.
Are reship guarantees worth anything?
Many overseas vendors offer to reship free if a package is seized. That is a real commercial practice, and it is informative.
Seizure is frequent enough to be priced in, which is the useful part. A vendor offering that guarantee has calculated the loss rate and built it into the price, which means you are paying for it whether or not your package is held.
It offers no legal protection and changes nothing about what happened to the first shipment. It is a refund policy expressed as a shipping term.
How long will customs hold my package?
Longer than people expect, and the uncertainty is most of the difficulty.
A package can sit in an examination hold for days to a few weeks before any decision is made. Tracking typically stops updating or shows a generic held or in-clearance status, which tells you nothing about which stage it is at.
If a notice is coming, it goes to the importer of record. On a personal order that is usually you, at the delivery address, by post. Many people never receive one at all, either because the shipment was refused at a stage that generates no notice to a private recipient, or because the vendor was listed as importer.
Silence is therefore not evidence either way. A package that has stopped moving for three weeks may be released, may be destroyed, and may simply be slow.
What your tracking status actually means
The only part of this you can observe directly, and the statuses are less informative than they look.
Held at customs
Any customs status confirms the package has entered the import process. It does not distinguish between a routine documentation check, a physical examination and an FDA referral, and those have very different outcomes.
In clearance, or awaiting clearance
Usually paperwork rather than inspection. Most packages showing this clear without anybody opening them.
A scan that simply stops
No status change for a week or more is the ambiguous case, and the most common cause of alarm. It can mean an examination hold, a backlog, or a carrier that updates poorly on international legs, and nothing visible to you distinguishes them.
A return to sender scan
The package is going back. That is less likely than destruction for a personal-value order of an unapproved drug, and it does happen where the goods were not classed as a drug.
None of the statuses tell you whether anybody has decided anything. Carrier tracking reports movement, and adjudication happens on a separate timetable that never appears on the page.
If you receive a notice
Most people will not. If you do, there are three things to know before deciding anything.
It has a deadline on it
The response window is short, typically around ten working days from the date on the notice, and the date is stated on the document itself.
Responding is a choice either way
Responding identifies you as the importer of an unapproved drug and commits you to a process. Staying silent sends the shipment to refusal and, for a personal-value order, destruction. Neither is obviously right and the amounts involved usually make the second the practical option.
A lawyer, if the value or quantity is significant
A few vials and a shipment large enough to look like distribution sit in different legal situations. Only the first of those counts as a paperwork problem.
Will your address get flagged?
The question people ask second, and the answer is partly.
Import alerts and automatic detention target shippers, products and countries of origin, not individual recipients.4 A vendor whose shipments are repeatedly refused sees its route degrade. Supply from that source then deteriorates gradually.
Refusals are recorded, and the importer of record on a refused shipment is part of that record. How far that affects subsequent personal shipments to the same address is not published at that level, which means anyone offering you a confident answer is guessing.
Why shipping got harder in 2025 and 2026
Through 2025 and into 2026, industry accounts describe shipments that previously cleared being held, tested or seized, with import lead times moving from around two weeks to six or eight.5
Our coverage of the FDA warning letters describes the same shift from the other direction, aimed at sellers rather than shipments, and our piece on the compounded semaglutide position covers a third front. All three are the same enforcement posture, aimed at shipments, sellers and pharmacies in turn.
Customs rules outside the United States
The picture varies enormously and one country stands out.
Australia classifies most peptides as prescription-only medicines, and the Australian Border Force screens aggressively. Reported seizure rates there are among the highest anywhere. A personal import without a prescription sits straightforwardly outside the rules.
The United Kingdom, Canada and most of the European Union run prescription-medicine frameworks that reach similar outcomes by different routes. Our guide on whether peptides are legal covers the general shape, and the specifics remain national.
Anybody telling you a compound ships anywhere without difficulty is describing their shipping ambition, not the law where you live.
What to take from this
A domestic order carries no customs exposure
If that describes your situation, none of the above applies to you.
An overseas order carries a real and rising chance of loss
Not a criminal risk. A delivery risk, and one that has grown.
Pay attention to how you paid
A seized package is a non-delivery, and what you can recover depends entirely on the payment method. Our guide on what to do when a vendor vanishes covers the mechanics, and the deadlines are shorter than people expect.
A reship guarantee is worth what the vendor is worth
It is a promise from the same company that just lost your order.
Where this stops being useful
Whether a specific shipment will clear, which nobody can predict.
The law where you live, which is national and changes.
Anything about quantities large enough to look commercial, which is a different legal situation and one for a lawyer.
Common questions
Will my peptides get seized?
If you ordered domestically and the package never crosses a border, customs plays no part. For international orders the risk is real and has risen through 2025 and 2026.
What are the odds my package gets seized?
Nobody publishes a usable figure. Vendors will not publish one. Refusal data is not broken out for personal peptide shipments, and forum reports are self-selecting in both directions. What can be said is that vendors now price reshipping into their offers and that reported lead times have lengthened.
My tracking has not updated in two weeks. What does that mean?
It could be an examination hold, a backlog, or poor carrier reporting on an international leg. There is no way to tell from outside, and tracking reports movement rather than any decision.
What happens if customs holds my package?
The shipment is detained, a notice is issued, and there is a window to respond. For a personal-value order of an unapproved drug, the likely outcome is destruction and not return.
Can I get in trouble for a seized package?
An import refusal is an administrative decision about goods, not a criminal matter. Refusals are recorded, and repeated ones against a shipper can trigger automatic detention of future shipments.
Do I get my money back?
Not from customs. Whether you recover anything depends on how you paid and on the vendor's policy, and a seizure counts as a non-delivery for dispute purposes.
I ordered from a US website. Am I safe?
Only if it ships from the US. A domestic order is not the same as a domestic shipment, and plenty of US-facing sites ship from overseas. The tracking number usually tells you, at the first scan.
How long will customs hold my package?
Days to a few weeks for an examination hold, and tracking generally stops updating or shows a generic status during it. So silence tells you nothing in either direction.
Should I respond if I get a notice?
Responding identifies you as the importer of an unapproved drug and commits you to a process. Not responding means refusal and, for a personal-value order, destruction. For a few vials the second is usually the practical choice, and a significant value or a commercial-looking quantity is a question for a lawyer.
Will my address be flagged?
Import alerts target shippers, products and countries of origin more than individual recipients. Refusals are recorded, and how far that affects later shipments to the same address is not published anywhere, so anyone confident about it is guessing.
Does "research use only" help at the border?
No. The FDA assesses what the product is, and our legality guide covers why that label does less than its prominence suggests.
Are reship guarantees real?
They are a genuine commercial practice, and they tell you seizure is common enough to be priced in. They are a refund policy, not a legal protection.
Is the personal importation policy an exemption?
It is discretionary and not an entitlement. The criteria describe a serious condition with no domestic treatment and a physician involved, which is some distance from an online order.
Why is shipping taking so much longer?
Industry accounts through 2025 and 2026 describe lead times moving from around two weeks to six or eight. Those accounts come from sellers rather than regulators.
Sources
- Section 801 of the Federal Food, Drug, and Cosmetic Act, 21 USC 381, as applied in FDA's Regulatory Procedures Manual, Chapter 9. Statute and implementing procedure, read at source. Section 801(a) provides for refusal of admission where "it appears from the examination of such samples or otherwise" that the article is adulterated, misbranded or an unapproved new drug. The manual notes that detention need not rest on a comprehensive examination, nor invariably on examination of a sample, because the statutory test is appearance of violation. The statutory text itself should also be linked directly before publication. ↩
- Division of responsibility between CBP and the FDA at the border. CBP screens and holds incoming shipments; the FDA makes the admission decision under section 801 and issues the Notice of FDA Action. This division is described throughout the Regulatory Procedures Manual cited above and in FDA's import programme pages. An earlier draft of this page stated that CBP's own materials list peptides specifically among regulated biological materials. That claim rested on a commercial peptide website citing a CBP document we had not seen, and it has been removed rather than repeated. If the CBP document exists it would be worth citing; until it is located, the narrower statement above is what the available sourcing supports. ↩
- FDA. Regulatory Procedures Manual, Chapter 9: Import Operations and Actions and Import Refusals. Regulatory procedure documents, read at source. Standard practice gives the owner or consignee ten working days from the date of detention to respond, with extensions possible. A refused shipment must be destroyed or exported under CBP supervision within 90 days of the Notice of Refusal, per 21 USC 381. The manual further states that where an article is a drug, is valued at $2,500 or less, and is adulterated, misbranded or an unapproved new drug in violation of section 505, the refused product will be destroyed without providing the owner or consignee with the opportunity to export. For all other articles, refused goods are generally returned to sender. That $2,500 threshold is the distinction this page turns on and it should be verified against the current version of the manual, which is periodically revised. ↩
- FDA. Actions and Enforcement and Import Alert 66-40. Regulatory documentation, read via search result. Import alerts inform FDA field staff that the agency has sufficient evidence to allow Detention Without Physical Examination of products subject to the alert. Where a product appears to be in violation, a Notice of FDA Action is issued specifying the nature of the violation and providing an opportunity to present supporting evidence within a specified period, with extensions available on request. Import Alert 66-40 additionally directs divisions to follow Regulatory Procedures Manual Chapter 9-2 for personal importation shipments, which is the provision separating personal shipments from the commercial framework described on this page. Both should be read in full before publication. ↩
- Reported increases in peptide interdiction and import lead times, 2025 to 2026. Reported across commercial and industry sources describing shipments that previously cleared being held, tested or seized, and import lead times moving from approximately two weeks to six or eight. Every source for this claim has a commercial position in the peptide market. None is a regulatory or trade publication, and no primary data supports it. The body text attributes it to industry accounts rather than stating it as established, and says plainly that those accounts come from sellers. FDA publishes import refusal data, which is the right basis for a trend claim of this kind, and a reader-facing figure should not be quoted until that data has been checked. ↩